Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Autogel every 14 days in progressive pancreatic or midgut neuroendocrine tumors
2014-005607-24Phase 2Completed
- Sponsor
- Ipsen
- Start
- Jul 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lanreotide in apudoma (NET), islet cell tumor and midgut neuroendocrine tumor (MNET), sponsored by Ipsen. Primary endpoint: Median progression-free survival. Started Jul 2015; status: completed.
02
Drugs
lanreotide
03
Conditions
apudoma (NET)islet cell tumormidgut neuroendocrine tumor (MNET)
Beyond the preview
Go deeper on 2014-005607-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005607-24.